 Shares of Gilead Sciences Inc. were down 0.1 in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos failed a Phase 3 clinical trial. Shares of Galapagos were down 3.5. 